Christopher Bowden Agios Pharmaceuticals, Inc. (AGIO) insider trading activity

Christopher Bowden is Chief Medical Officer of AGIOS PHARMACEUTICALS, INC.. Currently has a direct ownership of 15,487 shares of AGIO, which is worth approximately $734,548. The most recent transaction as insider was on Jun 18, 2021, when has been sold 48,493 shares (Common Stock) at a price of $60.11 per share, resulting in proceeds of $2,914,914. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15.5K

0% 3M change

0% 12M change

Total Value Held $734,548

Christopher Bowden Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 18 2021	SELL Open market or private sale	$2,914,914 $60.11 p/Share	48,493 Reduced 75.79%	15,487 Common Stock
Jun 18 2021	BUY Exercise of conversion of derivative security	$2,186,065 $45.08 p/Share	48,493 Added 43.12%	63,980 Common Stock
Jun 17 2021	SELL Open market or private sale	$150,170 $60.02 p/Share	2,502 Reduced 13.91%	15,487 Common Stock
Jun 17 2021	BUY Exercise of conversion of derivative security	$99,480 $39.76 p/Share	2,502 Added 12.21%	17,989 Common Stock
Jun 10 2021	SELL Open market or private sale	$1,252,431 $60.06 p/Share	20,853 Reduced 57.38%	15,487 Common Stock
Jun 10 2021	BUY Exercise of conversion of derivative security	$829,115 $39.76 p/Share	20,853 Added 36.46%	36,340 Common Stock
Jun 09 2021	SELL Open market or private sale	$430,084 $60.16 p/Share	7,149 Reduced 31.58%	15,487 Common Stock

Jun 09 2021	BUY Exercise of conversion of derivative security	$284,244 $39.76 p/Share	7,149 Added 24.0%	22,636 Common Stock
Jun 08 2021	SELL Open market or private sale	$400,967 $60.07 p/Share	6,675 Reduced 30.12%	15,487 Common Stock
Jun 08 2021	BUY Exercise of conversion of derivative security	$265,398 $39.76 p/Share	6,675 Added 23.15%	22,162 Common Stock
Jun 07 2021	SELL Open market or private sale	$256,251 $60.04 p/Share	4,268 Reduced 21.6%	15,487 Common Stock
Jun 07 2021	BUY Exercise of conversion of derivative security	$169,696 $39.76 p/Share	4,268 Added 17.77%	19,755 Common Stock
Apr 20 2021	SELL Open market or private sale	$793,639 $55.11 p/Share	14,401 Reduced 48.18%	15,487 Common Stock
Apr 20 2021	BUY Exercise of conversion of derivative security	$539,461 $37.46 p/Share	14,401 Added 32.52%	29,888 Common Stock
Apr 19 2021	SELL Open market or private sale	$177,064 $55.16 p/Share	3,210 Reduced 17.17%	15,487 Common Stock
Apr 19 2021	BUY Exercise of conversion of derivative security	$112,864 $35.16 p/Share	3,210 Added 14.65%	18,697 Common Stock
Feb 24 2021	SELL Payment of exercise price or tax liability	-	986 Reduced 6.01%	15,410 Common Stock
Feb 22 2021	BUY Exercise of conversion of derivative security	-	3,334 Added 16.9%	16,396 Common Stock
Feb 16 2021	SELL Payment of exercise price or tax liability	-	2,069 Reduced 13.67%	13,062 Common Stock
Feb 16 2021	BUY Exercise of conversion of derivative security	-	2,750 Added 15.38%	15,131 Common Stock
Feb 14 2021	BUY Exercise of conversion of derivative security	-	4,000 Added 24.42%	12,381 Common Stock

Also insider at

TCRT

Alaunos Therapeutics, Inc. Healthcare

Director